Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants
Alternative PJP prophylaxis carries risk of breakthrough infection and barriers to initiation. Since most recovered from adverse effects of TMP-SMX and tolerated resumption, providers should re-trial TMP-SMX when feasible.
Authors
- Kevin D. He
- Maxwell Norris (ORCID: https://orcid.org/0000-0002-4425-1050)
- Chelsea Sammons (ORCID: https://orcid.org/0000-0002-9071-9662)
- Emily A. Blumberg (ORCID: https://orcid.org/0000-0002-5193-6170)
- Jennifer Trofe‐Clark (ORCID: https://orcid.org/0000-0003-4370-3796)
- Stephanie Witek (ORCID: https://orcid.org/0000-0002-0279-2844)
- Tamara Claridge (ORCID: https://orcid.org/0000-0002-8002-9123)
- Abigail Forte
- Linh Nguyen (ORCID: https://orcid.org/0009-0000-5696-6478)
- Gregory Malat
Institutions
- Hospital of the University of Pennsylvania (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1111/tid.14410
- Citations
- 7
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Veloxis Pharmaceuticals